山楂消脂胶囊对痰湿体质肥胖症的减重作用

Weight-reduction Effect of Shanzha Xiaozhi Capsules on Obesity Patients with Phlegm-Dampness Constitution

【目的】研究山楂消脂胶囊(由山楂、大黄、甘草等组成)对痰湿体质肥胖症患者的体质量、代谢指标及身体脂肪含量和分布的影响。【方法】将50例痰湿体质肥胖症患者随机分成对照组和药物组各25例。对照组患者给予包括饮食和运动等方面的生活方式指导,药物组在生活方式指导的基础上,给予山楂消脂胶囊口服,疗程为12周。比较2组患者治疗前后的痰湿计分、体质量、腰围、臀围、血压、血糖、血脂、尿酸、身体脂肪含量和分布,以及内脏脂肪量的变化。【结果】(1)治疗后,2组患者的痰湿计分均显著下降(P<0.05或P<0.01),且药物组的下降作用更显著(P<0.01)。(2)治疗后,2组患者的体质量及体质量指数(BMI)均显著下降(P<0.01),且药物组的下降程度更显著(P<0.05);对照组治疗后的腰围无显著性变化(P>0.05),而药物组治疗后的腰围显著缩小(P<0.05);2组治疗后的臀围均显著缩小(P<0.05或P<0.01),但组间比较差异无统计学意义(P>0.05)。(3)治疗后,2组患者的收缩压和舒张压均有一定程度下降(P<0.01),但2组间收缩压和舒张压的下降程度比较,差异均无统计学意义(P>0.05)。(4)2组治疗前后的空腹血糖、葡萄糖负荷后2 h血糖、血脂、尿酸均无显著性变化(P>0.05)。(5)治疗后,2组患者的全身脂肪含量均显著下降(P<0.05或P<0.01),且药物组的下降程度更显著(P<0.01);2组治疗后的下肢、躯干及髋部脂肪含量均显著下降(P<0.05或P<0.01),但2组下降程度比较,差异无统计学意义(P>0.05);对照组治疗后的腰部脂肪含量无显著性变化(P>0.05),而药物组治疗后显著下降(P<0.01);2组治疗后的内脏脂肪量均显著下降(P<0.01),且药物组的下降程度更显著(P<0.01)。【结论】山楂消脂胶囊对痰湿体质肥胖症患者不但可降低体质量,还有减少内脏脂肪的作用。

Objective To investigate the effect of Shanzha Xiaozhi Capsules （SXC） on body weight, metabolic indexes, body fat accumulation and distribution of obesity patients with phlegm-dampness constitution. Methods Fifty obesity patients with phlegm-dampness constitution were randomized into control group and medicine group, 25 cases in each group. The control group was given lifestyle instructions for diet and exercises, and the medicine group was treated with SXC orally besides the instructions for lifestyle. The treatment for both groups covered 12 weeks. Before and after treatment, we observed the outcomes including scores of phlegm-dampness, body weight, waist circumference, hip circumference, blood pressure, fasting blood glucose, serum lipid profile, urine acid, body fat accumulation and distribution, and visceral fat accumulation. Results （1） The scores of phlegm-dampness were decreased significantly in both groups after treatment （P〈 0.05 or P 〈 0.01） , and the decrease was obvious in the medicine group（P 〈 0.01 ）. （2） Body weight and BMI were decreased significantly in both groups after treatment（P 〈 0.01）, and the decrease was obvious in the medicine group（P 〈 0.05）. Waist circumference was decreased significantly in the medicine group（P 〈 0.05） but stayed unchanged in the control group（P 〉 0.05）. Hip circumference was decreased significantly in both groups（P 〈 0.05 or P 〈 0.01）, but the difference between the two groups was insignificant（P 〉 0.05）. （3） Systolic pressure and diastolic pressure were decreased significantly in both groups （P 〈 0.01 ）. But the difference of blood pressure decrease between the two groups was insignificant（P 〉 0.05 ）. （4） Fasting blood glucose, 2-hour blood glucose after oral glucose tolerance test, serum lipid profile and urine acid remained unchanged in both groups after treatment （P 〉 0.05）. （5） The general body fat accumulation of both groups was decreased significantly after treatment （P 〈 0.05 or P 〈 0.01） , and the decrease was obvious in the medicine group （P 〈 0.01 ）. Body fat accumulation in legs, trunk and gynoid region were decreased significantly in both groups after treatment （P 〈 0.05 or P〈 0.01）, but the difference of fat accumulation decrease between the two groups was insignificant（P〉0.05）. Waist fat accumulation had no significant decrease in the control group （P 〉 0.05）, but was decreased in the medicine group （P〈0.01）. Visceral fat accumulation was decreased significantly in both groups after treatment（P 〈 0.01） , and the decrease was obvious in the medicine group （P 〈 0.01）. Conclusion In addition to its contribution to body weight loss, SXC also contribute to the reduction of visceral fat accumulation in obesity patients with phlegm-dampness constitution.